FDA Calls For Third-Party Auditor To Rectify Actavis Manufacturing Problems
FDA is recommending that Actavis "promptly initiate" a third-party audit program to oversee the correction of manufacturing discrepancies at the firm's Little Falls, N.J. facility, following the second warning letter for the plant in less than five months
You may also be interested in...
FDA's final guidance on studying the effects of inhaled and intranasal corticosteroids on growth in children narrows the recommended lower age limit for patients to three years of age
Sens. Byron Dorgan, D-S.D., and Olympia Snowe, R-Maine, are trying to build momentum for their proposal to allow prescription drug importation, vowing at a March 7 hearing that they will push to bring the measure quickly to the Senate floor
Icelandic generics firm has received two warning letters concerning its New Jersey manufacturing plant.